Inflectra®/CT-P13* (infliximab) is therapeutically comparable to Remicade® in RA18,20,35. 

ACR20 response in adult patients with active RA18,20,35

Plantra Efficacy Results

  • All efficacy endpoints were comparable during long-term treatment in the maintenance and switch groups20


A comparable safety profile to Remicade® was demonstrated by Inflectra® /CT-P13* (infliximab) which was maintained long term in RA18,20,35.

Treatment-emergent adverse events (TEAE)18,20,37

Planetra Safety Results


Click here to read about PLANETAS

Prescribing Information 

Inflectra® Summary of Product Characteristics   |   Legal Category: POM  Basic NHS Price: 1 vial £377.66

*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.
ҩ Therapeutic equivalence of clinical response according to ACR20 criteria was concluded if the 95% CI for the treatment difference was within ± 15%18.
ɣ Primary endpoint.
# ITT population

RA, Rheumatoid Arthritis; CI, Confidence interval; ITT, Intention-to-treat; PP, Per-protocol.


PP-IFA-GBR-0288. December 2018